John DiPersio

Researchers at the School of Medicine have been awarded $13.7 million from the National Cancer Institute (NCI) to create new therapies for multiple myeloma, a cancer of the immune system.​ Led by Samuel Achilefu, PhD, (pictured) and Gregory Lanza, MD, PhD, at the newly created Center for Multiple Myeloma Nanotherapy, scientists will work to develop nanomaterials and drugs to treat the disease.

John DiPersio, MD, PhD, the Virginia E. and Sam J. Golman Professor of Medicine at Washington University School of Medicine in St. Louis, has been named to the American Cancer Society’s National Medical Advisory Group for Patient Lodging.

Researchers led by John F. DiPersio, MD, PhD, at the School of Medicine have designed a way to mitigate graft-versus-host disease, a common and often life-threatening complication of bone marrow transplants that are used to treat leukemia and other blood cancers. The method also employs a molecular imaging tool to help doctors identify patients most likely to develop this dangerous condition.

Missouri Gov. Jay Nixon signed legislation Wednesday, March 19, on the Medical Campus to increase the affordability and accessibility of oral chemotherapy medications. ​

​John DiPersio, MD, PhD, chief of the Division of Oncology at Washington University School of Medicine in St. Louis, and Robert Schreiber, PhD, director of the school’s Center for Human Immunology and Immunotherapy Programs, will be honored in April by the American Association for Cancer Research.

The National Cancer Institute has awarded two major grants totaling $26 million to leukemia researchers and physicians at the School of Medicine. The funding has the potential to lead to novel therapies for leukemia that improve survival and reduce treatment-related side effects. Pictured are cancer cells from a patient with acute myeloid leukemia.